REMARKS/ARGUMENTS

Claims 40, 59-64; 66 are pending in the application.

Amendments in the specification and in the claims have been made to correct typographical errors appearing therein.

In response to the Restriction Requirement, the Applicants has restricted the claims to the claims of Group 1, namely claims 40-49, 51-54, 56-57, 59-64 and 66 drawn to products of the Formula (I). This restriction is made with traverse. The Applicant respectfully submits that all the claims of Groups I-III share a single general inventive concept, namely the compounds of Formula (I) and should therefore be part of the same invention.

The Applicant reserves the right to file one or more applications to capture the non-elected subject matter.

Election

The Examiner has required that the Applicant elects one species of a particular compound for examination. In response, the Applicant hereby elects the

compound

the

4-oxo-4-(6-

phenylimidazo[2,1-b][1,3,4]thiadiazole-2-sulfonamido)butanoic acid

Support for this compound within the specification can be found; at pg 2-3, at table 1 (pg 6), in example 22 (pg 28 –paragraph 0121) and in table 8 (pg 25).

As requested by the Examiner, the exact substitution as defined as follows: R1=H, R2= -C(O)CH2CH2CO2H, R5=H, R6=Ph, a=2, p=1, m=0.

It is finally respectfully submitted that in order to be responsive, the claims have been amended to be directed to the elected species and that therefore, all claims as presently pending are directed to the elected species.

If any fees with respect to the present application are due, the United States Patent and Trademark Office is hereby authorized to charge such fees to **Deposit Account no. 50-4067.**

Respectfully submitted,

GOWLING LAFLEUR HENDERSON, LLP

Date: December 17, 2008

Valérie Carrier Reg. No. 56,011 1 Place Ville-Marie 37th Floor Montreal, Quebec H3B 3P4

CANADA

Tel.: (514) 392-9562 Fax: (514) 878-1450

Enc.

Our Reference: L80003400US